Form 4: Virpax Pharmaceuticals Director Katharyn Field Acquires Stock Options
SEC Form 4 Filing
Director Katharyn Field acquired 2,500 stock options in Virpax Pharmaceuticals on July 5, 2024, at an exercise price of $0.578.
Summary
- On July 5, 2024, Katharyn Field, a director of Virpax Pharmaceuticals, Inc., acquired 2,500 stock options.
- The exercise price of these options is $0.578.
- The options vest in full on the twelve-month anniversary of the grant date.
- Following the transaction, Ms. Field directly owns 2,500 derivative securities.
- The options expire on July 4, 2034.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a standard disclosure related to insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of executive compensation packages.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/05/2024 | Date of transaction: Katharyn Field acquired stock options. |
| 07/04/2034 | Expiration date of the stock options. |
Keywords
stock options, Form 4, director, VRPX, Virpax Pharmaceuticals, Katharyn Field, beneficial ownership, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.